HomeAI · summaries
Storia in 2 fonti
AstraZeneca pays up to $1.5B for EGFR lung cancer drug Zegfrovy from its spinoff Dizal
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront
AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.
- ·
fiercepharma.com
AstraZeneca pays up to $1.5B for EGFR lung cancer drug Zegfrovy from its spinoff Dizal
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is
